Business Context and Reporting Period
Company: Cardinal Health, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 1996 (First Quarter of Fiscal 1997)
Business Overview: The Company operates primarily in pharmaceutical distribution and related services. Financial statements have been restated to reflect the pooling-of-interests mergers with Medicine Shoppe International, Inc. (November 1995) and Pyxis Corporation (May 1996).
Key Financial Metrics
| Metric | Q1 1997 (Sep 30, 1996) | Q1 1996 (Sep 30, 1995) |
|---|---|---|
| Net Revenues | $2,428,225,000 | $2,096,845,000 |
| Gross Margin | $182,263,000 (7.51%) | $164,046,000 (7.82%) |
| Operating Earnings | $70,619,000 | $56,688,000 |
| Net Earnings | $39,797,000 | $31,916,000 |
| Earnings Per Share (Diluted) | $0.61 | $0.49 |
| Cash and Equivalents | $110,513,000 | $73,431,000 |
| Working Capital | $940,800,000 | $854,100,000 (as of June 30, 1996) |
| Long-Term Obligations | $263,655,000 | $265,144,000 (as of June 30, 1996) |
Cash Flow Summary: Net cash used in operating activities was $179.3 million, primarily driven by a $310.4 million increase in merchandise inventories and a $41.9 million increase in trade receivables. Net cash provided by financing activities was $18.7 million.
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 16% year-over-year, driven by internal growth in pharmaceutical distribution, new customer additions, and price increases. A significant contributor was the expansion of the relationship with Kmart Corporation.
- Margin Compression: Gross margin percentage decreased to 7.51% from 7.82%. This decline is attributed to a shift in revenue mix toward lower-margin pharmaceutical distribution activities, partially offset by merchandising programs.
- Expense Efficiency: Selling, general, and administrative (SG&A) expenses as a percentage of revenue improved to 4.60% from 5.12%, reflecting economies of scale and productivity gains from facility automation.
- Interest Expense: Increased by $1.9 million due to the issuance of $150 million in 6% Notes in January 1996.
- Liquidity: Cash and equivalents decreased by $177.3 million from the prior quarter due to the timing of inventory purchases and payments.
Outlook, Risks, and Unusual Items
- PCI Merger: The Company completed a merger with PCI Services, Inc. on October 11, 1996, accounted for as a pooling-of-interests. A one-time charge for transaction costs is expected in the second quarter of fiscal 1997.
- Stock Split: A three-for-two stock split was declared on October 29, 1996, to be distributed on December 16, 1996. Financial statements will reflect this in the second quarter of fiscal 1997.
- Legal Proceedings: The Company is a defendant in consolidated antitrust litigation regarding brand name prescription drug pricing. Summary judgment was granted in the Company's favor in April 1996, but plaintiffs have appealed. Management does not believe the outcome will have a material adverse effect.
- Merger Costs: Costs related to prior mergers (Medicine Shoppe and Pyxis) totaled $67.3 million. Approximately $24.9 million had been paid through September 30, 1996, with no material difference expected in final estimates.
Investor Verification Checklist
- Verify the impact of the Kmart pharmaceutical services agreement on future revenue stability and margin mix.
- Monitor the timing and magnitude of the one-time PCI merger transaction costs expected in Q2 fiscal 1997.
- Assess the sustainability of working capital requirements given the significant inventory build-up ($310.4 million increase) relative to cash flow.
- Review the status of the appealed antitrust litigation to ensure no unexpected liabilities arise.
- Confirm the effective date and accounting treatment of the three-for-two stock split in subsequent filings.